Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection

AIDS

Volumn 12, Issue 6, 1998, Pages 571-579

  McAdam, Stephen ^a,d   Kaleebu, Pontiano ^b   Krausa, Peter ^a,e   Goulder, Philip ^a   French, Neil ^b   Collin, Beth ^a   Blanchard, Tom ^a   Whitworth, Jimmy ^b   McMichael, Andrew ^a   Gotch, Frances ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e PERKINELMER INC   (United States)

Author keywords

Africa; CD8; Cellular immunity; Vaccine

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UGANDA; UNITED KINGDOM; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 6844250759     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199806000-00005     Document Type: Article

References (30)

1. Walker C, Moody D, Stites, D, Levy J: CD8 lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986, 234:1563-1566.
2. Koup R, Safrit JT, Cao Y: Temporal association of cellular immune responses with the initial control of viraemia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
3. Safrit J, Koup R: The immunology of primary HIV infection: which immune responses control HIV replication? Curr Opin Immunol 1995, 7:456-461.
4. Carmichael A, Jin X, Sissons P, Borysiewicz L: Quantitative analysis of the human HIV-1 specific cytotoxic T-lymphocyte (CTL) response at different stages of infection: differential CTL responses to HIV-1 and Epstein Barr virus in late disease. J Exp Med 1993, 177:249-256.
5. Ariyoshi K, Cham F, Berry N, Jaffar S, Sabally S, Corrah T, Whittle H: HIV-2-specific cytotoxic T-lymphocyte activity is inversely related to proviral load. AIDS 1995, 9:555-559.
6. Moss P, Rowland-Jones S, Frodsham P, et al.: Persistent high frequency of HIV specific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci USA 1995, 92:5773-5777.
7. Cheynier R, Langlade-Demoyen P, Marescot MR, et al.: Cytotoxic T-lymphocyte responses in the peripheral blood of children born to HIV-1 infected mothers. Eur J Immunol 1992, 22:2211-2217.
8. Aldhous MC, Watret KC, Mok JY, Bird AG, Froebel KS: Cytotoxic T-lymphocyte activity and CD8 subpopulations in children at risk of HIV infection. Clin Exp Immunol 1994, 97:61-67.
9. Rowland-Jones S, Nixon D, Aldous M, et al.: HIV specific CTL activity in an HIV-exposed but uninfected infant. Lancet 1993, 341:860-861.
10. Langlade-Demoyen P, Ngo N, Ferchal F, Oksenhendler E: HIV nef-specific cytotoxic T-lymphocytes in non-infected heterosexual contact of HIV-infected patients. J Clin Invent 1994, 93:1293-1297.
11. Rowland-Jones S, Sutton J, Ariyoshi K, et al.: HIV-specific cytotoxic T cells in HIV-exposed but uninfected Gambian women. Nature Med 1995, 1:59-64.
12. Gallimore A, Cranage M, Cook N, et al.: Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nature Med 1995, 1:1167-1173.
13. Rubsamen-Waigmann H, von Briesen H, Holmes H, et al.: Standard conditions of virus isolation reveal biological variability of HIV type 1 in different regions of the world. AIDS Res Hum Retroviruses 1994, 10:1401-1408.
14. Louwagie J, McCutchan IE, Peeters M, et al.: Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS 1993, 7:769-780.
15. Zachar V, Goustin A, Zacharova V, et al.: Genetic polymorphism of envelope V3 region of HIV type 1 subtypes A, C and D from Nairobi, Kenya. AIDS Res Hum Retroviruses 1996, 12:75-78.
16. Weber J, Fenyo EM, Beddows S, Kaleebu P, Bjorndal A: Neutralisation serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO network for HIV isolation and characterisation. J Virol 1996, 70:7827-7832.
17. Moore J, Trkola A: HIV type 1 coreceptors, neutralization subtypes, and vaccine development. AIDS Res Hum Retroviruses 1997, 13:733-736.
18. McAdam S, Klenerman P, Tussey L, et al.: Immunogenic variants that bind to HLA-B8 but fail to stimulate CTL responses. J Immunol 1995, 155:2729-2736.
19. Phillips R, Rowland-Jones S, Nixon D, et al.: Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991, 354:453-459.
20. Weber J, Cheinsong-Popov R, Callow D, et al.: Immunogenicity of the yeast recombinant p17/p24:ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine 1995, 13:831-834.
21. Bachmann MH, Delwart EL, Shpaer EG, Lingenfelter P, Singal R, Mullins JI: Rapid genetic characterization of HIV type 1 strains from four World Health Organization-sponsored vaccine evaluation sites using a heteroduplex mobility assay. AIDS Res Hum Retroviruses 1994, 10:1345-1353.
22. Bunce M, Fanning GC, Welsh KI: Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence specific primers (PCR-SSP). Tissue Antigens 1995, 45:81-90.
23. Bunce M, Barnado MC, Welsh KI: Improvements in HLA-C typing using sequence-specific primers (PCR-SSP) including definition of HLA-Cw9 and Cw10 and a new allele HLA-'Cw7/8v'. Tissue Antigens 1994, 44:200-203.
24. Moss B, Flexner C: Vaccinia virus expression vectors. Annu Rev Imunol 1987, 5:305-324.
25. Nixon D, Townsend A, Elvin J, Rizza C, Gotch F, McMichael A: HIV-1 gag-specific CTL defined with recombinant vaccinia viruses and synthetic peptides. Nature 1988, 336:484-487.
26. Autran B, Letvin NL: HIV epitopes recognised by cytotoxic T-lymphocytes. AIDS 1991, 5(suppl 2):S145-S150.
27. Gotch F, Nixon D, Gallimore A, McAdam S, McMichael A: Cytotoxic T lymphocyte epitopes shared between HIV-1, HIV-2, and SIV. J Med Primatol 1993, 22:119-123.
28. Marlink R, Kanki P, Thior I, et al.: Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994, 265:1587-1590.
29. Desrosiers RC: Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine. AIDS Res Hum Retroviruses 1994, 10:331-332.
30. Wyand M, Manson K, Garcia M, Montefiori D, Desrosiers R: Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 1996, 70:3724-3733.